Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases

To determine the clinical benefits of systemic targeted agents across multiple histologies after stereotactic radiosurgery (SRS) for brain metastases. Between 2000 and 2013, 737 patients underwent upfront SRS for brain metastases. Patients were stratified by whether or not they received targeted age...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2015-08, Vol.6 (22), p.18945-18955
Main Authors: Johnson, Adam G, Ruiz, Jimmy, Hughes, Ryan, Page, Brandi R, Isom, Scott, Lucas, John T, McTyre, Emory R, Houseknecht, Kristin W, Ayala-Peacock, Diandra N, Bourland, Daniel J, Hinson, William H, Laxton, Adrian W, Tatter, Stephen B, Debinski, Waldemar, Watabe, Kounosuke, Chan, Michael D
Format: Article
Language:English
Subjects:
Brain Neoplasms - drug therapy
Brain Neoplasms - secondary
Brain Neoplasms - surgery
Brain Neoplasms - therapy
Cohort Studies
Combined Modality Therapy
Disease-Free Survival
Female
Humans
Male
Middle Aged
Molecular Targeted Therapy
Neoplasm Metastasis
Radiosurgery - methods
Research Paper
Retrospective Studies
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine the clinical benefits of systemic targeted agents across multiple histologies after stereotactic radiosurgery (SRS) for brain metastases. Between 2000 and 2013, 737 patients underwent upfront SRS for brain metastases. Patients were stratified by whether or not they received targeted agents with SRS. 167 (23%) received targeted agents compared to 570 (77%) that received other available treatment options. Time to event data were summarized using Kaplan-Meier plots, and the log rank test was used to determine statistical differences between groups. Patients who received SRS with targeted agents vs those that did not had improved overall survival (65% vs. 30% at 12 months, p < 0.0001), improved freedom from local failure (94% vs 90% at 12 months, p = 0.06), improved distant failure-free survival (32% vs. 18% at 12 months, p = 0.0001) and improved freedom from whole brain radiation (88% vs. 77% at 12 months, p = 0.03). Improvement in freedom from local failure was driven by improvements seen in breast cancer (100% vs 92% at 12 months, p < 0.01), and renal cell cancer (100% vs 88%, p = 0.04). Multivariate analysis revealed that use of targeted agents improved all cause mortality (HR = 0.6, p < 0.0001). Targeted agent use with SRS appears to improve survival and intracranial outcomes.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.4153